KR102722304B1 - Uti 융합 단백질 - Google Patents

Uti 융합 단백질 Download PDF

Info

Publication number
KR102722304B1
KR102722304B1 KR1020227037377A KR20227037377A KR102722304B1 KR 102722304 B1 KR102722304 B1 KR 102722304B1 KR 1020227037377 A KR1020227037377 A KR 1020227037377A KR 20227037377 A KR20227037377 A KR 20227037377A KR 102722304 B1 KR102722304 B1 KR 102722304B1
Authority
KR
South Korea
Prior art keywords
gly
ser
val
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227037377A
Other languages
English (en)
Korean (ko)
Other versions
KR20220151005A (ko
Inventor
애런 챔벌린
퀴앙 리우
마티아스 슈미트
Original Assignee
다케다 게엠베하
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 게엠베하, 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 게엠베하
Priority to KR1020247035230A priority Critical patent/KR20240155987A/ko
Publication of KR20220151005A publication Critical patent/KR20220151005A/ko
Application granted granted Critical
Publication of KR102722304B1 publication Critical patent/KR102722304B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
KR1020227037377A 2014-02-24 2015-02-23 Uti 융합 단백질 Active KR102722304B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247035230A KR20240155987A (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
US61/943,617 2014-02-24
KR1020167026429A KR102461210B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167026429A Division KR102461210B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247035230A Division KR20240155987A (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Publications (2)

Publication Number Publication Date
KR20220151005A KR20220151005A (ko) 2022-11-11
KR102722304B1 true KR102722304B1 (ko) 2024-10-28

Family

ID=52629709

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227037377A Active KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020247035230A Pending KR20240155987A (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020167026429A Active KR102461210B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247035230A Pending KR20240155987A (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020167026429A Active KR102461210B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Country Status (38)

Country Link
US (4) US9856310B2 (enExample)
EP (2) EP3443978A1 (enExample)
JP (4) JP6574431B2 (enExample)
KR (3) KR102722304B1 (enExample)
CN (2) CN110092837B (enExample)
AR (1) AR101597A1 (enExample)
AU (4) AU2015218704B2 (enExample)
BR (1) BR112016019390B1 (enExample)
CA (2) CA2939639C (enExample)
CL (1) CL2016002136A1 (enExample)
CR (1) CR20160444A (enExample)
CY (1) CY1120997T1 (enExample)
DK (1) DK3110434T3 (enExample)
DO (1) DOP2016000202A (enExample)
EA (2) EA037256B1 (enExample)
EC (1) ECSP16076535A (enExample)
ES (1) ES2700149T3 (enExample)
GE (1) GEP20196970B (enExample)
HR (1) HRP20182029T1 (enExample)
IL (1) IL247321B (enExample)
JO (1) JO3729B1 (enExample)
LT (1) LT3110434T (enExample)
MA (1) MA39347B2 (enExample)
MX (4) MX2016010950A (enExample)
MY (1) MY178774A (enExample)
NZ (3) NZ724196A (enExample)
PE (1) PE20170257A1 (enExample)
PH (1) PH12016501629B1 (enExample)
PL (1) PL3110434T3 (enExample)
PT (1) PT3110434T (enExample)
RS (1) RS58285B1 (enExample)
SG (2) SG11201606691QA (enExample)
SI (1) SI3110434T1 (enExample)
SM (1) SMT201800674T1 (enExample)
TW (1) TWI694084B (enExample)
UA (1) UA118866C2 (enExample)
WO (1) WO2015127391A1 (enExample)
ZA (1) ZA201606327B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016010950A (es) * 2014-02-24 2017-04-25 Takeda Gmbh Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MY207281A (en) * 2017-06-07 2025-02-13 Spark Therapeutics Inc Enhancing agents for improved cell transfection and/or raav vector production
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044554A (zh) * 2012-05-14 2013-04-17 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (de) 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
AU641568B2 (en) 1990-11-13 1993-09-23 Mochida Pharmaceutical Co., Ltd. Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
EP1730191B1 (en) * 2004-03-30 2011-07-06 Glaxo Group Limited Immunoglobulin binding hosm
KR20070041781A (ko) 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
JP4067557B2 (ja) * 2005-06-03 2008-03-26 持田製薬株式会社 抗ｃｄ１４抗体融合蛋白質
AU2006332774A1 (en) 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
JP2012525847A (ja) * 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
KR101926663B1 (ko) * 2010-02-19 2018-12-07 젠코어 인코포레이티드 신규의 ＣＴＬＡ４-Ｉｇ 이뮤노어드헤신
ES2666303T3 (es) * 2011-04-29 2018-05-03 University Of Washington Composiciones terapéuticas de nucleasa y métodos
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
JP6138815B2 (ja) * 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
JP5855239B2 (ja) * 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
MX2016010950A (es) * 2014-02-24 2017-04-25 Takeda Gmbh Proteinas de fusion de inhibidor de tripsina urinaria (uti).

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044554A (zh) * 2012-05-14 2013-04-17 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用

Also Published As

Publication number Publication date
ZA201606327B (en) 2019-01-30
US10351618B2 (en) 2019-07-16
JP2017512058A (ja) 2017-05-18
JP2022002513A (ja) 2022-01-11
MX2016010950A (es) 2017-04-25
DK3110434T3 (en) 2019-01-14
KR20240155987A (ko) 2024-10-29
CR20160444A (es) 2017-04-21
AR101597A1 (es) 2016-12-28
AU2021225156B2 (en) 2022-11-24
US20160362475A1 (en) 2016-12-15
JO3729B1 (ar) 2021-01-31
CN110092837B (zh) 2024-01-02
NZ760008A (en) 2023-03-31
NZ724196A (en) 2022-01-28
EA201691702A1 (ru) 2017-01-30
CY1120997T1 (el) 2019-12-11
IL247321B (en) 2020-06-30
JP6574431B2 (ja) 2019-09-11
SMT201800674T1 (it) 2019-01-11
TWI694084B (zh) 2020-05-21
ECSP16076535A (es) 2017-08-31
SG10201708400QA (en) 2017-11-29
GEP20196970B (en) 2019-04-25
HRP20182029T1 (hr) 2019-02-08
CN106232135A (zh) 2016-12-14
US20180072795A1 (en) 2018-03-15
CN110092837A (zh) 2019-08-06
MX384070B (es) 2025-03-14
KR102461210B1 (ko) 2022-10-31
AU2015218704A1 (en) 2016-09-22
PT3110434T (pt) 2018-12-19
AU2015218704B2 (en) 2019-05-02
RS58285B1 (sr) 2019-03-29
KR20220151005A (ko) 2022-11-11
TW201630931A (zh) 2016-09-01
PH12016501629B1 (en) 2023-10-20
MX2024000004A (es) 2024-02-20
AU2021225156A1 (en) 2021-09-30
WO2015127391A1 (en) 2015-08-27
LT3110434T (lt) 2018-12-27
JP2019187427A (ja) 2019-10-31
US20200040062A1 (en) 2020-02-06
ES2700149T3 (es) 2019-02-14
CL2016002136A1 (es) 2017-08-11
CA3178241A1 (en) 2015-08-27
SG11201606691QA (en) 2016-09-29
NZ760789A (en) 2023-03-31
MA39347A1 (fr) 2018-06-29
MA39347B2 (fr) 2020-05-29
CA2939639C (en) 2023-01-24
BR112016019390A2 (pt) 2017-10-24
SI3110434T1 (sl) 2019-02-28
EP3443978A1 (en) 2019-02-20
CN106232135B (zh) 2019-12-10
BR112016019390B1 (pt) 2023-11-14
JP2023123763A (ja) 2023-09-05
PL3110434T3 (pl) 2019-01-31
EP3110434B1 (en) 2018-09-19
JP6938565B2 (ja) 2021-09-22
EP3110434A1 (en) 2017-01-04
PE20170257A1 (es) 2017-03-30
IL247321A0 (en) 2016-09-29
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
AU2023200875A1 (en) 2023-04-27
MX2019013124A (es) 2020-08-31
US20220127334A1 (en) 2022-04-28
CA2939639A1 (en) 2015-08-27
UA118866C2 (uk) 2019-03-25
EA202091567A1 (ru) 2021-07-30
MY178774A (en) 2020-10-20
AU2019204448A1 (en) 2019-07-11
EA037256B1 (ru) 2021-02-26
KR20160141718A (ko) 2016-12-09
PH12016501629A1 (en) 2017-02-06
US9856310B2 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
KR102722304B1 (ko) Uti 융합 단백질
KR20240051971A (ko) 액티빈 수용체 ii형 신호전달 억제제를 이용한 방법
CN101679497A (zh) 可溶性il-17ra/rc融合蛋白以及相关方法
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
JP2022512539A (ja) 併用療法
JP2021506772A (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
HK40004244A (en) Uti fusion proteins
HK40108366A (zh) 使用激活素受体ii型信号传导抑制剂的方法
HK1232783A1 (en) Uti fusion proteins
HK1232783B (en) Uti fusion proteins

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000